Biopharma & Life Sciences
Emergent BioSolutions Executive Compensation (FY25)
EBS · Executive and director compensation, fiscal 2023 to 2025
Data as of September 7, 2026Latest filing (8-K): April 30, 2026
259 figures on this page: 248 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
The disclosed peer group includes ACADIA Pharmaceuticals Inc., Alkermes plc, Amneal Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc., among others. Total compensation for Joseph Papa, President, Chief Executive Officer and Director, came to $5,321,147 in fiscal 2025, and compared with the $5,862,562 reported for fiscal 2024, Papa's total was 9.2% lower, while the company reported a chief executive pay ratio of 41:1 for fiscal 2025, against median employee compensation of $130,553. For fiscal 2025, shareholders backed the say-on-pay proposal with 60.3% of votes cast for or against in favor at the meeting held April 29, 2026.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Joseph Papa: $5,862,562 → $5,321,147 (9.2% lower)
Say-on-pay support: 84.3% → 60.3% (24.0 points lower)
CEO pay ratio: 48:1 → 41:1 (14.6% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Emergent BioSolutions' chief executive and what were they paid?
Total compensation for Joseph Papa, President, Chief Executive Officer and Director, came to $5,321,147 in fiscal 2025. Compared with the $5,862,562 reported for fiscal 2024, Papa's total was 9.2% lower.
What was Emergent BioSolutions' say-on-pay result?
For fiscal 2025, shareholders backed the say-on-pay proposal with 60.3% of votes cast for or against in favor at the meeting held April 29, 2026.
Which companies are in Emergent BioSolutions' peer group?
The disclosed peer group includes ACADIA Pharmaceuticals Inc., Alkermes plc, Amneal Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc. and ANI Pharmaceuticals, Inc., among others.
What is Emergent BioSolutions' chief executive pay ratio?
The company reported a chief executive pay ratio of 41:1 for fiscal 2025, against median employee compensation of $130,553.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Richard Lindahl Executive Vice President, Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Coleen Glessner Executive Vice President, Quality and Ethics and Compliance | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Paul Williams Senior Vice President, Products Business | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Joseph Papa President, Chief Executive Officer and Director | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Richard Lindahl Executive Vice President, Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Coleen Glessner Executive Vice President, Quality and Ethics and Compliance | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Paul Williams Senior Vice President, Products Business | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Joseph Papa President, Chief Executive Officer and Director | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Richard Lindahl Executive Vice President, Chief Financial Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Coleen Glessner Executive Vice President, Quality and Ethics and Compliance | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Simon Lowry Chief Medical Officer, Head of Research and Development | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Paul Williams Senior Vice President, Products Business | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Coleen Glessner | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Joseph Papa | PSU | ◇ | ◇ | ◇ | — | — | — | ◇ |
| Paul Williams | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Richard Lindahl | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Simon Lowry | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Richard Lindahl | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Coleen Glessner | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Paul Williams | RSU | ◇ | ◇ | — | — |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Simon Lowry | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Joseph Papa | Option | ◇ | — | ◇ | — |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Zsolt Harsanyi, Ph.D Board chair | ◇ | ◇ | — | — | — | — | ◇ |
Kathryn Zoon, Ph.D | ◇ | ◇ | — | — | — | — | ◇ |
Marvin White | ◇ | ◇ | — | — | — | — | ◇ |
Ronald Richard | ◇ | ◇ | — | — | — | — | ◇ |
Keith Katkin | ◇ | ◇ | — | — | — | — | ◇ |
Sujata Dayal | ◇ | ◇ | — | — | — | — | ◇ |
Neal Fowler | ◇ | ◇ | — | — | — | — | ◇ |
Louis Sullivan, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Donald DeGolyer | ◇ | ◇ | — | — | — | — | ◇ |
Joseph Papa and John Fowler, Jr served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
Equity is delivered as RSUs and Stock Options (50% RSUs / 50% stock options in 2025).
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- ACADIA Pharmaceuticals Inc. ACAD
- Alkermes plc ALKS
- Amneal Pharmaceuticals, Inc. AMRX
- Amphastar Pharmaceuticals, Inc. AMPH
- ANI Pharmaceuticals, Inc. ANIP
- Collegium Pharmaceutical, Inc. COLL
- CRISPR Therapeutics AG CRSP
- Dynavax Technologies Corporation DVAX
- Haemonetics Corporation HAE
- Integra LifeSciences Holdings Corporation IART
- Ionis Pharmaceuticals, Inc. IONS
- Myriad Genetics, Inc. MYGN
- OPKO Health, Inc. OPK
- Pacira BioSciences, Inc. PCRX
- PTC Therapeutics, Inc. PTCT
- Supernus Pharmaceuticals, Inc. SUPN
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | April 29, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | April 30, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | May 23, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 25, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | May 26, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | May 20, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | May 21, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | May 23, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | May 24, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | May 25, 2017 | = | ◇ | ◇ | ◇ |
| 2015 | May 19, 2016 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
What this page does not include
Everything above is a fact Emergent BioSolutions disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Emergent BioSolutions sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceSay-on-pay responsiveness
Emergent BioSolutions recorded a low support level. The responsiveness analysis covers what the company said it would do, what it did, and how that compares with the companies that recovered their vote.
Responsiveness analysisAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
259 figures on this page: 248 cited to the filing that reported them, 11 calculated from figures it prints.
248 cited to the filing
11 calculated from the filing
Documents cited
- 0001367644-26-000051Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001367644-26-0000332025 Outstanding Equity Awards At Fiscal Year End · 2025 Summary Compensation Table · 2026 Non-Employee Director Compensation Program · CEO Pay Ratio Disclosure · and 4 more sections
- 0001367644-25-000114Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001367644-25-0000802024 Summary Compensation Table
- 0001367644-24-000093Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-24-0934002023 Summary Compensation Table
- 0001367644-23-000112Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001367644-22-000080Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001367644-21-000099Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001367644-20-000082Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001367644-19-000027Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001367644-18-000025Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001367644-17-000024Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001367644-16-000066Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Emergent BioSolutions executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/EBS (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Emergent BioSolutions and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Emergent BioSolutions discloses
The companies named in EBS's own disclosed peer group.
Terms on this page
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}